Susceptibility testing of Mycobacterium avium complex isolates

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 8, 1996, Pages 1759-1767

  Heifets, Leonid ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CLINICAL TRIAL; DILUTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; RADIOMETRY; REVIEW; TREATMENT OUTCOME; TURBIDIMETRY;

EID: 0029795936     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.8.1759     Document Type: Review

References (117)

1. Agins, B. D., D. S. Berman, D. Spicehandler, W. El Sadr, M. S. Simberkoff, and J. J. Rahal. 1989. Effect of combined therapy with ansamycin, clofazimine, ethambutol and isoniazid for Mycobacterium avium infection in patients with AIDS. J. Infect. Dis. 159:734-737.
2. Ahn, C. H., S. S. Ahn, R. A. Anderson, D. T. Murphy, and A. Mammo. 1986. A four-drug regimen for initial treatment of cavitary disease caused by M. avium complex. Am. Rev. Respir. Dis. 134:438.
3. Ahn, C. H., J. W. McLarty, S. S. Ahn, S. I. Ahn, and G. A. Hurst. 1982 Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare. Am. Rev. Respir. Dis. 125:388.
4. Baron, J. E., and L. S. Young. 1986. Amikacin, ethambutol, and rifampin for treatment of disseminated M. avium-intracellulare infection in patients with acquired immune deficiency syndrome. Diagn. Microbiol. Infect. Dis. 5:215-220.
5. Bates, J. H. 1967. A study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis: clinical characteristics. XX. A report of the Veterans Administration - Armed Forces cooperative study on the chemotherapy of tuberculosis. Am. Rev. Respir. Dis. 96:1151-1157.
6. Benson, C. A., H. A. Kessler, J. C. Pottage, Jr., and G. M. Trenholme. 1991. Successful treatment of acquired immunodeficiency syndrome-related Mycobacterium avium complex disease with a multiple drug regimen including amikacin. Arch. Intern. Med. 151:582-585.
7. Chaisson, R. E., C. A. Benson, M. P. Dube, L. B. Heifets, J. A. Korvick, S. Elkin, T. Smith, C. Craft, F. R. Sattler, and AIDS Clinical Trial Group Protocol 157 Study Team. 1994. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease (a randomized, double-blind, dose-ranging study in patients with AIDS). Ann. Intern. Med. 121:905-911.
8. Chaisson, R. E., R. D. Moore, D. D. Richman, J. Keruly, and T. Creagh. 1992. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced HIV disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am. Rev. Respir. Dis. 146: 285-289.
9. Chiu, J., J. Nussbaum, S. Bozzette, J. G. Tilles, L. S. Young, and J. Leedom. 1990. Treatment of disseminated Mycobacterium avium complex infection with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann. Intern. Med. 113:358-361.
10. Christensen, E. E., G. W. Dietz, C. H. Ahn, J. S. Chapman, R. C. Murry, and G. A. Hurst. 1979. Pulmonary manifestations of Mycobacterium intracellulare. Am. J. Roentgenol. 133:59.
11. Cooksey, R. C., J. T. Crawford, W. R. Jacobs, Jr., and T. M. Shinnick. 1993. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob. Agents Chemother. 37:1348-1352.
12. Corpe, R. F. 1964. Clinical aspects, medical and surgical, in the management of Battey-type pulmonary disease. Chest 35:380-382.
13. Crow, H. E., C. T. King, C. E. Smith, R. F. Corpe, and I. Stergus. 1957. A limited clinical, pathologic and epidemiologic study of patients with pulmonary lesions associated with atypical acid-fast bacilli in the sputum. Am. Rev. Tuberc. 75:199.
14. Cynamon, M. H. 1985. Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulare. Antimicrob. Agents Chemother. 28:440-441.
15. Cynamon, M. H., G. S. Palmer, and T. B. Sorg. 1987. Comparative in vitro activities of ampicillin, BMY28142, and imipinem against M. avium complex. Diagn. Microbiol. Infect. 6:151.
16. Dautzenberg, B. 1994. Clinical trials in M. avium therapy: lessons to take home. Res. Microbiol. 145:197-206.
17. Dautzenberg, B., T. Saint Marc, M. C. Meyohas, M. Eliazewitch, F. Haniez, A. Rogues, S. De Wit, L. Cotte, J. P. Chauvin, and J. Grosset. 1993. Clarithromycin and other antimycobacterial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch. Intern. Med. 153:368-373.
18. Dautzenberg, B., C. Truffot, S. Legris, M. Meyohas, H. C. Berlie, A. Mercat, S. Chevret, and J. Grosset. 1991. Clarithromycin against Mycobacterium avium infection in AIDS patients: a controlled clinical trial. Am. Rev. Respir. Dis. 144:564-569.
19. Davidson, P. T., V. Kanijo, M. Goble, and T. S. Moulding. 1981. Treatment of disease due to Mycobacterium intracellulare. Rev. Infect. Dis. 3:1052-1053.
20. De Lalla, F., R. Maserati, and P. Scarpellini. 1992. Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. Antimicrob. Agents Chemother. 36:1567-1569.
21. Dutt, A. K., and W. W. Stead. 1979. Long-term results of medical treatment in Mycobacterium intracellulare infection. Am. J. Med. 67:449.
22. Falkinham, J. O., III, B. C. Parker, and H. Gruft. 1980. Epidemiology of infection by nontuberculous mycobacteria. Am. Rev. Respir. Dis. 121:931-937.
23. Fenlon, C. H., and M. H. Cynamon. 1986. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare. Antimicrob. Agents Chemother. 29:386-388.
24. Fischer, D. A., W. Lester, and W. B. Schaefer. 1968. Infections with atypical mycobacteria. Five years' experience at the National Jewish Hospital. Am. Rev. Respir. Dis. 98:29.
25. Good, R. C. 1980. Isolation of nontuberculous mycobacteria in the United States, 1979. J. Infect. Dis. 142:779.
26. Good, R. C. 1985. Opportunistic pathogens in genus Mycobacterium. Am. Rev. Respir. Dis. 39:347-369.
27. Good, R. C., and D. E. Snider, Jr. 1982. Isolation of nontuberculous mycobacteria in the United States, 1980. J. Infect. Dis. 146:829.
28. Gordon, S. M., C. R. Horsburgh, Jr., and C. A. Peloquin. 1993. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J. Infect. Dis. 168:1559-1562.
29. Grange, J., C. Collins, and M. Yates. 1982. Bacteriological survey of tuberculous lymphadenitis in southeast England: 1973-80. J. Epidemiol. Community Health 36:157-161.
30. Greene, J. B., G. S. Sidhu, S. Lewin, J. F. Levine, H. Masur, M. S. Simberkoff, P. Nicholas, R. C. Good, S. B. Zolla-Pazner, A. A. Pollock, M. L. Tapper, and R. S. Holzman. 1982. Mycobacterium avium-intracellulare: a cause of disseminated life-threatening infection in homosexuals and drug abusers. Ann. Intern. Med. 97:539.
31. Gruft, H., D. Blanchard, and J. Wheeler. 1976. Ocean waters a source of Mycobacterium intracellulare. Am. Rev. Respir. Dis. 113(No. 4, Part 2):60.
32. Gruft, H., J. O. Falkinham, and B. C. Parker. 1981. Recent experience in the epidemiology of disease caused by atypical mycobacteria. Rev. Infect. Dis. 3:990-996.
33. Hansen, S. L., P. Swomley, and G. Drusano. 1981. Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to crythromycin. Antimicrob. Agents Chemother. 19:335-336.
34. Hawkins, C. C., J. W. Gold, E. Whimbey, T. E. Kiehn, P. Brannon, R. Cammarata, A. E. Brown, and D. Armstrong. 1986. Mycobacterium avium complex infections in patients with acquired immunodeficiency syndrome. Ann. Intern. Med. 105:184-199.
35. Heifets, L., and P. Lindholm-Levy. 1989. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against M. avium and M. tuberculosis. Antimicrob. Agents Chemother. 33:1298-1301.
36. Heifets, L., P. Lindholm-Levy, J. Libonati, N. Hooper, A. Laszlo, M. Cynamon, and S. Siddiqi. 1993. Radiometric broth macrodilution method for determination of MIC with M. avium complex. Proposed guidelines. National Jewish Center for Immunology and Respiratory Medicine, Denver, Colo.
37. Heifets, L., N. Mor, and J. Vanderkolk. 1993. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob. Agents Chemother. 37:2364-2370.
38. Heifets, L. B. 1988. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob. Agents Chemother. 32:1131-1136.
39. Heifets, L. B. 1988. Qualitative and quantitative drug susceptibility tests in mycobacteriology. Am. Rev. Respir. Dis. 37:1217.
40. Heifets, L. B. 1991. Antituberculosis drugs: antimicrobial activity in vitro, p. 89-122. In L. B. Heifets (ed.), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Inc., Boca Raton, Fla.
41. Heifets, L. B. 1991. Dilemmas and realities in drug susceptibility testing of M. avium-M. intracellulare and other slowly growing nontuberculous mycobacteria, p. 123-146. In L. B. Heifets (ed.), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Inc., Boca Raton, Fla.
42. Heifets, L. B. 1991. Drug combinations, p. 179-200. In L. B. Heifets (ed.), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Inc., Boca Raton, Fla.
43. Heifets, L. B. 1994. Quantitative cultures and drug susceptibility testing of M. avium clinical isolates before and during the antimicrobial therapy. Res. Microbiol. 145:188-196.
44. Heifets, L. B., and M. D. Iseman. 1990. Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility. N. Engl. J. Med. 323:419-420.
45. Heifets, L. B., and M. D. Iseman. 1991. Individualized therapy versus standard regimens in the treatment of M. avium infections. Am. Rev. Respir. Dis. 144:1-2.
46. Heifets, L. B., M. D. Iseman, and P. J. Lindholm-Levy. 1986. Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 30:927-932.
47. Heifets, L. B., and P. J. Lindholm-Levy. 1987. Bacteriostatic and bactericidal activities of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle 68:267-276.
48. Heifets, L. B., P. J. Lindholm-Levy, and R. D. Comstock. 1992. Clarithromycin minimal inhibitory and bactericidal concentrations against M. avium. Am. Rev. Respir. Dis. 145:856-858.
49. Heifets, L. B., P. J. Lindholm-Levy, and M. A. Flory. 1990. Bactericidal activity in vitro of various rifamycins against M. avium and M. tuberculosis. Am. Rev. Respir. Dis. 141:626-630.
50. Hoover, D. R., A. J. Saab, H. Bacellar, J. Phair, R. Detels, and R. Anderson. 1993. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N. Engl. J. Med. 329:1922-1926.
51. Hopewell, P., M. Cynamon, J. Starke, M. Iseman, and R. O'Brien. 1992. Evaluation of new anti-infective drugs for the treatment and prevention of infections caused by the Mycobacterium avium complex. Clin. Inf. Dis. 15(Suppl. 1):S296-S306.
52. Horsburgh, C. R., Jr. 1991. Current concepts: Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N. Engl. J. Med. 324:1332.
53. Horsburgh, C. R., Jr., D. P. Chin, and D. M. Yajko. 1994. Environmental risk factors for acquisition of Mycobacterium avium complex in persons with human immunodeficiency virus infection. J. Infect. Dis. 170:362-367.
54. Horsburgh, C. R., Jr., J. A. Havlik, and D. A. Ellis. 1991. Survival of AIDS patients with disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am. Rev. Respir. Dis. 144: 557-559.
55. Horsburgh, C. R., Jr., U. G. Mason III, L. B. Heifets, K. Southwick, J. Labrecque, and M. D. Iseman. 1987. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am. Rev. Respir. Dis. 135:418-421.
56. Horsburgh, C. R., Jr., B. Metchock, and S. Gordon. 1994. Predictors of survival of patients with AIDS and disseminated Mycobacterium avium complex disease. J. Infect. Dis. 170:573-577.
57. Horsburgh, C. R., Jr., and R. M. Selik. 1989. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am. Rev. Respir. Dis. 139:4-7.
58. Hoy, J., A. Mijch, M. Sandlum, L. Grayson, R. Lucas, and B. Dwyer. 1990. Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients. J. Infect. Dis. 161:801-805.
59. Hunter, A. M., I. A. Campbell, P. A. Jenkins, and A. P. Smith. 1981. Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex. Thorax 36:326.
60. Inderlied, C. B., and K. A. Nash. 1996. Microbiology and in vitro susceptibility testing, p. 109-195. In J. A. Korvick and C. A. Benson (ed.), Mycobacterium avium complex infection. Marcel Dekker, Inc., New York.
61. Iseman, M. D. 1989. Mycobacterium avium complex and the normal host (the other side of the coin). N. Engl. J. Med. 321:896. (Editorial.)
62. Iseman, M. D., R. F. Corpe, R. J. O'Brien, D. Y. Rosenzweig, and E. Wolinsky. 1985. Disease due to Mycobacterium avium-intracellulare. Chest 87:139S-145S.
63. Isenberg, H. D. 1988. Antimicrobial susceptibility testing: a critical review. J. Antimicrob. Chemother. 22(Suppl. A):73-75.
64. Jacobs, W. R., R. G. Barletta, R. Udani, J. Chan, G. Kalkut, G. Sosne, T. Kieser, G. J. Sarkis, G. F. Hatfull, and B. R. Bloom. 1993. Rapid assessment of drug susceptibility of M. tuberculosis by means of luciferase reporter phages. Science 260:819-822.
65. Kemper, C. A., D. Havlir, D. Haghighat, M. Dube, A. E. Bartok, and J. P. Sison. 1994. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol and rifampin on Mycobacterium avium complex bacteremia in patients with AIDS. J. Infect. Dis. 170:157-164.
66. Kemper, C. A., T. C. Meng, J. Nussbaum, J. Chiu, D. F. Fiegal, and A. E. Bartok. 1992. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug regimen: rifampin, ethambutol, clofazimine, and ciprofloxacin. Ann. Intern. Med. 116:466-472.
67. Kennedy, T., and D. Weber. 1994. Nontuberculous mycobacteria: an underappreciated cause of geriatric lung disease. Am. J. Respir. Crit. Care Med. 149:1654-1658.
68. Kiehn, T. E., F. F. Edwards, P. Brennan, A. Y. Tsang, M. Maio, J. W. M. Gold, E. Whimbly, B. Wong, J. K. McClatchy, and D. Armstrong. 1985 Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics. J. Clin. Microbiol. 21:168-173.
69. Korvick, J. A., and C. A. Benson. 1996. Advances in treatment and prophylaxis of M. avium complex in individuals infected with HIV, p. 241-283. In J. A. Korvick and C. A. Benson (ed.), Mycobacterium avium complex infection. Marcel Dekker, Inc., New York.
70. Kuze, F., T. Kurasawa, K. Bando, Y. Lee, and N. Maekawa. 1981. In vitro and in vivo susceptibility of atypical mycobacteria to various drugs. Rev. Infect. Dis. 3:885-889.
71. Lee, C. N., and L. B. Heifets. 1987. Determination of minimal inhibitory concentrations of antituberculosis drugs. Am. Rev. Respir. Dis. 136:349-352.
72. Lester, W., D. A. Fischer, T. S. Moulding, R. I. Fraser, and J. K. McClatchy. 1968. Evaluation of chemotherapy responses in group III (Battey-type) mycobacterial infections, p. 20. In Transactions of the 27th Veterans Administration - Armed Forces Pulmonary Disease Research Conference. USGPO, Washington, D.C.
73. Lester, W., T. Moulding, R. I. Fraser, and J. K. McClatchy. 1969. Quintuple drug regimens in the treatment of Battey-type infections, p. 83. In Transactions of the 28th Veterans Administration - Armed Forces Pulmonary Disease Research Conference. USGPO, Washington, D.C.
74. Lewis, A. G., F. P. Dunbar, R. J. Davies, E. M. Lasche, E. N. Lerner, D. J. Wharton, and J. O. Bond. 1958. Clinical evaluations of 100 patients with chronic pulmonary disease due to or associated with atypical mycobacteria. Am. Rev. Tuberc. Pulmonary Dis. 78:315-319.
75. Lewis, A. G., E. M. Lasche, A. L. Armstrong, and F. P. Dunbar. 1960. A clinical study of the chronic lung disease due to nonphotochromogenic acid-fast bacilli. Ann. Intern. Med. 53:273.
76. Lincoln, E. M., and L. A. Gilbert. 1972. Disease in children due to mycobacteria other than M. tuberculosis. Am. Rev. Respir. Dis. 105:683.
77. Lorian, V., and L. D. Sabath. 1970. Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli. Appl. Microbiol. 20: 754-756.
78. Masur, H., C. Tuazon, and V. Gill. 1987. Effect of combined clofazimine and ansamycin therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. J. Infect. Dis. 155:127-129.
79. Masur, H., and U.S. Public Health Service Task Force on Prophylaxis and Therapy for M. avium Complex. 1993. Recommendations on prophylaxis and therapy for disseminated M. avium complex disease in patients infected with the HIV N. Engl. J. Med. 329:898-904. (Special Report.)
80. Meier, A., R. J. Wallace, P. Sander, L. Heifets, and E. C. Böttger. 1995. Molecular mechanisms of resistance to clarithromycin in mycobacteria, abstr. U-41, p. 124. In Abstracts of the 95th General Meeting of the American Society for Microbiology 1995. American Society for Microbiology, Washington, D.C.
81. Mor, N., and L. Heifets. 1993. MIC and MBC of clarithromycin against Mycobacterium avium within human macrophages. Antimicrob. Agents Chemother. 37:111-114.
82. Mor, N., B. Simon, N. Mezo, and L. Heifets. 1995. Comparison of the activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 39:2073-2077.
83. Mor, N., J. Vanderkolk, and L. Heifets. 1994. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob. Agents Chemother. 38:1161-1164.
84. National Committee for Clinical Laboratory Standards. 1992. Performance standards for antimicrobial susceptibility testing. In J. H. Jorgensen (ed.), Standard M100-S4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
85. Nightingale, S. D., L. T. Byrd, P. M. Southern, J. D. Jockusch, S. X. Cal, and B. A. Wynne. 1992. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J. Infect. Dis. 165:1082-1985.
86. O'Brien, R. J., L. J. Geiter, and D. E. Snider. 1987. The epidemiology of nontuberculous mycobacterial diseases in the United States: results from a national survey. Am. Rev. Respir. Dis. 135:1007-1014.
87. Parker, B. C., M. A. Ford, H. Gruft, and J. O. Falkinham. 1983 Epidemiology of infection by nontuberculous mycobacteria. IV. Preferential aerosolization of M. intracellulare from natural waters. Am. Rev. Respir. Dis. 128:652-656.
88. Perrone, C., A. Gikas, C. Truffot-Pernot, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1991. Activities of sparfloxacin, azithromycin, temafloxacin and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob. Agents Chemother. 35:1356-1359.
89. Pransky, S. M., B. K. Reisman, and D. B. Kearns. 1990. Cervicofacial mycobacterial adenitis in children: endemic to San Diego? Laryngoscope 100:920-925.
90. Prince, D. S., D. D. Peterson, R. M. Steiner, J. E. Gottlieb, R. Scott, H. L. Israel, W. G. Fignerova, and J. E. Fish. 1989. Infection with M. avium complex in patients without predisposing conditions. N. Engl. J. Med. 321:863.
91. Reich, J., and R. Johnson. 1991. Mycobacterium avium complex pulmonary disease. Incidence, presentation, and response to therapy in a community setting. Am. Rev. Respir. Dis. 143:1381-1385.
92. Ruf, B., D. Schürmann, H. Mauch, G. Jautzke, F. J. Fehrenbach, and H. D. Pohle. 1992. Effectiveness of the macrolide clarithromycin in the treatment of Mycobacterium avium complex infection in HIV-infected patients. Infection 20:267-272.
93. Seydel, J. K., K. J. Schaper, and S. Rüsch-Gerdes. 1992. Development of effective drug combinations for the inhibition of multiply resistant mycobacteria especially of the Mycobacterium avium complex. Chemotherapy (Basel) 38:159-168.
94. Siddiqi, S. M., L. B. Heifets, M. H. Cynamon, N. M. Hooper, A. Laszlo, J. P. Libonati, P. J. Lindholm-Levy, and N. Pearson. 1993. Rapid growth macrodilution method for determination of MICs for Mycobacterium avium isolates. J. Clin. Microbiol. 31:2332-2338.
95. Sison, J., Y. Yao, C. Kemper, J. R. Hamilton, E. Brummer, D. A. Stevens, and S. C. Deresinki. 1966. Treatment of Mycobacterium avium compex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans? J. Infect. Dis. 173:677-683.
96. Spark, R. P., M. L. Fried, and C. K. Bean. 1988. Nontuberculous mycobacterial adenitits of childhood. The ten-year experience at a community hospital. Am. J. Dis. Child. 142:106-108.
97. Swenson, J. M., C. Thornsberry, and V. A. Silcox. 1982. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob. Agents Chemother. 22:186-192.
98. Swenson, S., T. Hartman, and D. Williams. 1994. Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest 105:49-52.
99. Taha, A. M., P. T. Davidson, and W. C. Biiley. 1985. Surgical treatment of atypical mycobacterial lymphadenitis in children. Pediatr. Infect. Dis. 4:664-667.
100. Telenti, A., P. Imboden, and F. Marchesi. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647-650.
101. Truffot-Pernot, C., B. Ji, and J. Grosset. 1991. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob. Agents Chemother. 35:1677-1678.
102. Tsukamura, M. 1988. Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infections caused by Mycobacterium avium complex. Am. Rev. Respir. Dis 137:144-148.
103. Tsukamura, M., N. Kita, H. Shimoide, H. Arakawa, and A. Kuze. 1988. Studies on the epidemiology of nontuberculous mycobacterioses in Japan. Am. Rev. Respir. Dis. 137:1280-1284.
104. Tsukamura, M., H. Shimoide, N. Kita, K. Kawakami, T. Ito, N. Nakajima, N. Kondo, and Y. Yamamoto. 1981. Epidemiologic studies of lung disease due to mycobacteria other than Mycobacterium tuberculosis in Japan. Rev. Infect. Dis. 3:997-1007.
105. Wallace, R. J., Jr., B. A. Brown, E. Griffith, W. M. Girard, D. T. Murphy, G. O. Onyi, V. A. Steingrube, and G. H. Mazurek. 1994. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am. J. Respir. Crit. Care Med. 149:1335-1341.
106. Wallace, R. J., Jr., D. R. Nash, L. C. Steel, and S. V. Steingrube. 1986. Susceptibility testing of slowly growing mycobacteria in microdilution MIC method with 7H9 broth. J. Clin. Microbiol. 24:976-981.
107. Wendt, S. G., K. L. George, B. C. Parker, H. Croft, and J. O. Falkinham. 1980. Epidemiology of infection by nontuberculous mycobacteria. III. Isolation of potentially pathogenic mycobacteria from aerosols. Am. Rev. Respir. Dis. 112:259-263.
108. Williams, D. L., C. Waguespack, T. P. Gillis, K. Eisenach, J. Crawford, F. Portaels, M. Salfinger, C. M. Nolan, C. Abe, and V. Sticht-Groh. 1994. Characterization of rifampin resistance in pathogenic mycobacteria. Antimicrob. Agents Chemother. 38:2380-2386.
109. Wolinsky, E. 1979. Nontuberculosis mycobacteria and associated diseases. Am. Rev. Respir. Dis. 119:107-159.
110. Wong, B., F. F. Edwards, T. E. Kiehn, E. Whimbey, H. Donnelly, E. M. Bernard, J. W. M. Gold, and D. Armstrong. 1985. Continuous high grade Mycobacterium avium intracellulare bacteremia in patients with the acquired immune deficiency syndrome. Am. J. Med. 78:35-40.
111. Woods, G. L., and J. A. Washington. 1987. Mycobacteria other than M. tuberculosis: a review of microbiologic and clinical aspects. Rev. Infect. Dis. 9:275-294.
112. Yajko, D. M., P. S. Nassos, and W. K. Hadley. 1987. Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immunodeficiency syndrome. Antimicrob. Agents Chemother. 31:1579-1584.
113. Yajko, D. M., P. T. Nassos, C. A. Sanders, P. C. Gonzalez, and W. K. Hadley. 1992. Comparison of the intracellular activities of clarlithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells in alveolar macrophages from human immunodeficiency virus 1-infected individuals. Antimicrob. Agents Chemother. 36:1163-1165.
114. Yeager, H., and J. W. Raleigh. 1973. Pulmonary disease due to Mycobacterium intracellulare. Am. Rev. Respir. Dis. 108:547.
115. Young, L. S., C. B. Inderlied, O. G. Berlin, and M. S. Gottlieb. 1986. Mycobacterial infections in AIDS patients, with emphasis on the Mycobacterium avium complex. Rev. Infect. Dis. 81:1024.
116. Young, L. S., L. Wiviott, M. Wu, P. Kolonoski, R. Bolan, and C. B. Inderlied. 1991. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 338:1107-1109.
117. Zakowski, P., S. Fligiel, G. W. Berlin, and B. L. Johnson, Jr. 1982. Disseminated Mycobacterium avium-intracellulare infection in homosexual men dying of acquired immunodeficiency. JAMA 248:2980.